$TMO

Jim Cramer Calls Big Tech ‘Millstones’ and Names the ‘New Techs’ Taking Over

Jim Cramer on Mad Money criticized big tech companies like Alphabet, Amazon, and Meta, calling them 'millstones' and instead favoring life sciences suppliers. He highlighted Thermo Fisher Scientific (TMO), Agilent Technologies (A), and Waters (WAT) as new tech leaders, citing strong performance and FDA support. TMO is up 20.5% YTD, A up 28.9%, and WAT up 22.1%. Cramer awaits more confirmation before re-entering tech, noting recent NASDAQ-100 decline.

Original reporting
Published Nov 4, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jim Cramer Calls Big Tech ‘Millstones’ and Names the ‘New Techs’ Taking Over — source image
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The article provides no fresh data beyond existing earnings reports; it is an opinion piece that may influence short‑term sentiment toward the highlighted stocks.

02

Market read

Commentary may spark modest interest in life‑sciences instrument stocks but lacks new material information.

03

What to watch

Potential supply‑chain constraints and government budget pressures could limit life‑sciences spend.

Relevance 4/10Novelty 2/10Timing: today

Background

Jim Cramer argues that life‑sciences suppliers could become the next tech leaders, citing recent earnings beats from Thermo Fisher, Agilent and Waters.

Company-level read

Ticker impact

$TMONeutralHigh confidence
Context

Thermo Fisher reported Q3 revenue up 9.1% and EPS beat, with stock up 20.5% YTD.

Expected impact

limited upside as earnings already priced in

Evidence & confidence

Quarterly numbers were expected; market likely to hold current levels.

$ABullishMedium confidence
Context

Agilent highlighted 28.9% YTD gain and raised FY EPS guidance.

Expected impact

potential modest upside on guidance lift

Evidence & confidence

Guidance increase is a positive signal but limited scale.

$WATBullishMedium confidence
Context

Waters posted organic revenue growth and raised 2026 EPS guidance.

Expected impact

possible modest upside on guidance raise

Evidence & confidence

Guidance improvement is new but market impact likely modest.

Market effects

Life‑sciences instrument sector highlighted as potential new tech theme.

U.S. market sentiment may shift modestly toward lab‑equipment stocks.

Limited; commentary primarily U.S. investor focus.

Counterpoint

Cramer’s shift may be premature; traditional megacap tech still dominates performance.

Key entities

  • Jim Cramer

    Host of Mad Money, providing market commentary.

  • Thermo Fisher Scientific

    Life‑sciences supplier mentioned with earnings beat.

  • Agilent Technologies

    Life‑sciences supplier with raised guidance.

  • Waters Corporation

    Life‑sciences supplier with raised guidance.

Related articles

$AMedAI 9/10

Agilent completes acquisition of Proscia for $240 million

Agilent Technologies (NYSE:A) completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The acquisition adds a recurring-revenue software business to Agilent’s pathology portfolio. Agilent generated $6.95 billion in revenue in fiscal year 2025.

$AHighAI 8/10

Software for examining tissue, trusted by 16 of the top 20 drug companies, now belongs to Agilent.

Agilent Technologies (A) completed the acquisition of Proscia, a digital pathology platform trusted by 16 of the top 20 drug companies. The deal expands Agilent’s pathology portfolio, adding a recurring-revenue software business and enhancing its AI-enabled pathology workflows. Proscia’s platform has FDA 510(k) clearance for primary diagnosis and supports clinical diagnostics, biopharma, and life-sciences research.

$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

$WATMedAI 8/10

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.